drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting CD19 on B cells for treatment of CD19+ B-cell non-Hodgkin lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes CD19 on B cells. CAR engagement activates CD3zeta and costimulatory domains (e.g., CD28 or 4-1BB), driving T-cell proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD19+ malignant B cells.
drug_name
CD19-directed CAR T cells
nct_id_drug_ref
NCT05665725